NCI Funds 24 DNA Microarray Laboratories Nationwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

BETHESDA, Md-Twenty-four cancer research centers in the United States will receive a total of $4.1 million from the National Cancer Institute to purchase the necessary equipment to establish DNA microarray facilities. The new and technically challenging research tool enables scientists to assess expression levels of a large subset of the human genes in a cell or tissue.

BETHESDA, Md—Twenty-four cancer research centers in the United States will receive a total of $4.1 million from the National Cancer Institute to purchase the necessary equipment to establish DNA microarray facilities. The new and technically challenging research tool enables scientists to assess expression levels of a large subset of the human genes in a cell or tissue.

The NCI intends for the DNA microarray laboratories to provide technical support to cancer researchers and to make the technology widely available so that it is rapidly applied to investigating a broad range of critical problems in cancer research.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content